ReviewACS chemical biology2018
Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations.
Review in ACS chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 315 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
315 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Assessing Chikungunya Virus Protease Activity and Pharmacological Inhibition Using the acc-CHIKMethods in molecular biology (Clifton, N.J.) · 2027Article
- Small Molecule Insulin Sensitisers: New Leads and Targets for Next-Generation Insulin Sensitising Strategies.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Discovery of a new SARS-CoV-2 Mpro inhibitor from a natural product and natural product-like compound database using in silico and in vitro studies.Molecular diversity · 2026Article
- Oxadiazolone-Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II-Induced Vascular Contraction.ChemMedChem · 2026Article
- Discovery of CDK8/19 inhibitors as lead compounds for IL-6-dependent lymphoma enabled by the formal synthesis of cortistatin A.Science advances · 2026Article
- Unveiling the anticancer potential of genus Aerva as therapeutics for CLL (Chronic Lymphocytic Leukemia): from plant to patient.Folia microbiologica · 2026Article
- In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.SLAS discovery : advancing life sciences R & D · 2026Article
- Combinatorial group testing for efficient scaling across biological applications.Nature communications · 2026Article
- Pomegranate (Veterinary sciences · 2026Review
- Bidentate Metal-Binding Motifs in US FDA Approved Small Molecule Drugs.Journal of medicinal chemistry · 2026Review
- Effect of Polyphenols Derived from Medicinal Plants on Multiple Myeloma via Modulating Bone Marrow Microenvironment.Chinese journal of integrative medicine · 2026Review
- Dual enzymatic inhibition and toxicity profiling of polymethoxylated flavones isolated from Knema malayana.Journal of computer-aided molecular design · 2026Article
- ImagiChem: Hybrid Deterministic Image-Conditioned Generation of Chemically Valid and Drug-like Molecules from Artistic Inputs.ACS omega · 2026Article
- Identification and characterization of novel chikungunya virus polymerase inhibitors.Journal of virology · 2026Article
- Structure-guided compound prioritization strategy for virtual screening identifies putative binders for the nuclear receptor LRH-1.bioRxiv : the preprint server for biology · 2026Article
- Article
- From code to cure: computational identification of LasR inhibitors to combat quorum sensing in P. aeruginosa.Molecular diversity · 2026Article
- Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.Nature chemical biology · 2026Article
- Deep learning for assay nuisance compound detection using a gated co-attention graph embedding model (CAGE-Fusion).Journal of cheminformatics · 2026Article
255 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pan-Assay Interference Compounds (PAINS) are very familiar to medicinal chemists who have spent time fruitlessly trying to optimize these nonprogressible compounds. Electronic filters formulated to recognize PAINS can process hundreds and thousands of compounds in seconds and are in widespread current use to identify PAINS in order to exclude them from further analysis. However, this practice is fraught with danger because such black box treatment is simplistic. Here, we outline for the first time all necessary considerations for the appropriate use of PAINS filters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.